REFERENCES

1. Akshata Desai, K. A. (2012). Triple Negative Breast Cancer – An Overview. Hereditary Genetics. https://doi.org/10.4172/2161-1041.S2-001

2. Aktar, A., Vrieze, A. M., Telesnicki, K., Cox-Duvall, P., Arbolino, M., DeKoter, R. P., Nagpal, A. D., & Heit, B. (2025). GATA2 induces a stem cell–like transcriptional program in macrophages that promotes an atherogenic phenotype. Journal of Leukocyte Biology, 117(10). https://doi.org/10.1093/jleuko/qiaf136

3. Ankasha, S. J., Shafiee, M. N., Wahab, N. A., Ali, R. A. R., & Mokhtar, N. M. (2018). Post-transcriptional regulation of microRNAs in cancer: From prediction to validation. Oncology Reviews. https://doi.org/10.4081/oncol.2018.344

4. Ardito, F., Giuliani, M., Perrone, D., Troiano, G., & Muzio, L. Lo. (2017). The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review). International Journal of Molecular Medicine, 40(2), 271–280. https://doi.org/10.3892/ijmm.2017.3036

5. Aum, D. J., Kim, D. H., Beaumont, T. L., Leuthardt, E. C., Dunn, G. P., & Kim, A. H. (2014). Molecular and cellular heterogeneity: The hallmark of glioblastoma. Neurosurgical Focus, 37(6). https://doi.org/10.3171/2014.9.FOCUS14521

6. Baumgart, S., Ellenrieder, V., & Fernandez-Zapico, M. E. (2013). Oncogenic transcription factors: cornerstones of inflammation-linked pancreatic carcinogenesis. Gut, 62(2), 310–316. https://doi.org/10.1136/gutjnl-2011-301008

7. Beck, B. H., & Welch, D. R. (2010). The KISS1 metastasis suppressor: A good night kiss for disseminated cancer cells. European Journal of Cancer, 46(7), 1283–1289. https://doi.org/10.1016/j.ejca.2010.02.023

8. Behrooz, A. B., & Syahir, A. (2021). Could We Address the Interplay Between CD133, Wnt/β-Catenin, and TERT Signaling Pathways as a Potential Target for Glioblastoma Therapy? Frontiers in Oncology, 11. https://doi.org/10.3389/fonc.2021.642719

9. Binder, Z. A., Thorne, A. H., Bakas, S., Wileyto, E. P., Bilello, M., Akbari, H., Rathore, S., Ha, S. M., Zhang, L., Ferguson, C. J., Dahiya, S., Bi, W. L., Reardon, D. A., Idbaih, A., Felsberg, J., Hentschel, B., Weller, M., Bagley, S. J., Morrissette, J. J. D., … O'Rourke, D. M. (2018). Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development. Cancer Cell, 34(1), 163-177.e7. https://doi.org/10.1016/j.ccell.2018.06.006

10. Biran, J., Ben-Dor, S., & Levavi-Sivan, B. (2008). Molecular Identification and Functional Characterization of the Kisspeptin/Kisspeptin Receptor System in Lower Vertebrates1. Biology of Reproduction, 79(4), 776–786. https://doi.org/10.1095/biolreprod.107.066266

11. Blake, A., Dragan, M., Tirona, R. G., Hardy, D. B., Brackstone, M., Tuck, A. B., Babwah, A. V., & Bhattacharya, M. (2017). G protein-coupled KISS1 receptor is overexpressed in triple negative breast cancer and promotes drug resistance. Scientific Reports, 7. https://doi.org/10.1038/srep46525

12. Brown, D. V., Stylli, S. S., Kaye, A. H., & Mantamadiotis, T. (2019). Multilayered Heterogeneity of Glioblastoma Stem Cells: Biological and Clinical Significance (pp. 1–21). https://doi.org/10.1007/978-3-030-14366-4_1

13. Brunelle, J. K., & Letai, A. (2009). Control of mitochondrial apoptosis by the Bcl-2 family. Journal of Cell Science, 122(4), 437–441. https://doi.org/10.1242/jcs.031682

14. Bruner, H. C., & Derksen, P. W. B. (2018). Loss of E-Cadherin-Dependent Cell–Cell Adhesion and the Development and Progression of Cancer. Cold Spring Harbor Perspectives in Biology, 10(3), a029330. https://doi.org/10.1101/cshperspect.a029330

15. Cao, Z.-Q., Wang, Z., & Leng, P. (2019). Aberrant N-cadherin expression in cancer. Biomedicine & Pharmacotherapy, 118, 109320. https://doi.org/10.1016/j.biopha.2019.109320

16. Carneiro, B. A., & El-Deiry, W. S. (2020). Targeting apoptosis in cancer therapy. Nature Reviews Clinical Oncology, 17(7), 395–417. https://doi.org/10.1038/s41571-020-0341-y

17. Casas, E., Kim, J., Bendesky, A., Ohno-Machado, L., Wolfe, C. J., & Yang, J. (2011). Snail2 is an Essential Mediator of Twist1-Induced Epithelial Mesenchymal Transition and Metastasis. Cancer Research, 71(1), 245–254. https://doi.org/10.1158/0008-5472.CAN-10-2330

18. Castaño, J. P., Martínez-Fuentes, A. J., Gutiérrez-Pascual, E., Vaudry, H., Tena-Sempere, M., & Malagón, M. M. (2009). Intracellular signaling pathways activated by kisspeptins through GPR54: Do multiple signals underlie function diversity? Peptides, 30(1), 10–15. https://doi.org/10.1016/j.peptides.2008.07.025

19. Castro-Piedras, I., Vartak, D., Sharma, M., Pandey, S., Casas, L., Molehin, D., Rasha, F., Fokar, M., Nichols, J., Almodovar, S., Rahman, R. L., & Pruitt, K. (2020). Identification of Novel MeCP2 Cancer-Associated Target Genes and Post-Translational Modifications. Frontiers in Oncology, 10. https://doi.org/10.3389/fonc.2020.576362

20. Cho, S.-G., Yi, Z., Pang, X., Yi, T., Wang, Y., Luo, J., Wu, Z., Li, D., & Liu, M. (2009). Kisspeptin-10, a KISS1-Derived Decapeptide, Inhibits Tumor Angiogenesis by Suppressing Sp1-Mediated VEGF Expression and FAK/Rho GTPase Activation. Cancer Research, 69(17), 7062–7070. https://doi.org/10.1158/0008-5472.CAN-09-0476

21. Ciaramella, V., Della Corte, C. M., Ciardiello, F., & Morgillo, F. (2018). Kisspeptin and Cancer: Molecular Interaction, Biological Functions, and Future Perspectives. Frontiers in Endocrinology, 9. https://doi.org/10.3389/fendo.2018.00115

22. Cvetković, D., Babwah, A. V., & Bhattacharya, M. (2013a). Kisspeptin/KISS1R System in Breast Cancer. Journal of Cancer, 4(8), 653–661. https://doi.org/10.7150/jca.7626

23. Cvetković, D., Babwah, A. V., & Bhattacharya, M. (2013b). Kisspeptin/KISSIR system in breast cancer. In Journal of Cancer (Vol. 4, Number 8, pp. 653–661). https://doi.org/10.7150/jca.7626

24. Dashti, S., Taheri, M., & Ghafouri-Fard, S. (2020). An in-silico method leads to recognition of hub genes and crucial pathways in survival of patients with breast cancer. Scientific Reports, 10(1), 18770. https://doi.org/10.1038/s41598-020-76024-2

25. Davis, M. (2016). Glioblastoma: Overview of Disease and Treatment. Clinical Journal of Oncology Nursing, 20(5), S2–S8. https://doi.org/10.1188/16.CJON.S1.2-8

26. de Roux, N., Genin, E., Carel, J.-C., Matsuda, F., Chaussain, J.-L., & Milgrom, E. (2003). Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. Proceedings of the National Academy of Sciences, 100(19), 10972–10976. https://doi.org/10.1073/pnas.1834399100

27. De Vleeschouwer, S. (Ed.). (2017). Glioblastoma. Codon Publications. https://doi.org/10.15586/codon.glioblastoma.2017

28. De Wever, O., Pauwels, P., De Craene, B., Sabbah, M., Emami, S., Redeuilh, G., Gespach, C., Bracke, M., & Berx, G. (2008). Molecular and pathological signatures of epithelial–mesenchymal transitions at the cancer invasion front. Histochemistry and Cell Biology, 130(3), 481. https://doi.org/10.1007/s00418-008-0464-1

29. DeCordova, S., Shastri, A., Tsolaki, A. G., Yasmin, H., Klein, L., Singh, S. K., & Kishore, U. (2020). Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma. Frontiers in Immunology, 11. https://doi.org/10.3389/fimmu.2020.01402

30. Ding, X.-M. (2014). MicroRNAs: regulators of cancer metastasis and epithelial-mesenchymal transition (EMT). Chinese Journal of Cancer, 33(3), 140–147. https://doi.org/10.5732/cjc.013.10094

31. Drápela, S., Bouchal, J., Jolly, M. K., Culig, Z., & Souček, K. (2020). ZEB1: A Critical Regulator of Cell Plasticity, DNA Damage Response, and Therapy Resistance. Frontiers in Molecular Biosciences, 7. https://doi.org/10.3389/fmolb.2020.00036

32. Dratwa, M., Wysoczańska, B., Łacina, P., Kubik, T., & Bogunia-Kubik, K. (2020). TERT—Regulation and Roles in Cancer Formation. Frontiers in Immunology, 11. https://doi.org/10.3389/fimmu.2020.589929

33. Duan, H., Ding, X., & Luo, H. (2022). KISS-1, Mediated by Promoter Methylation, Suppresses Esophageal Squamous Cell Carcinoma Metastasis via MMP2/9/MAPK Axis. Digestive Diseases and Sciences, 67(10), 4780–4796. https://doi.org/10.1007/s10620-021-07335-1

34. Falco, J., Agosti, A., Vetrano, I. G., Bizzi, A., Restelli, F., Broggi, M., Schiariti, M., Dimeco, F., Ferroli, P., Ciarletta, P., & Acerbi, F. (2021). In silico mathematical modelling for glioblastoma: A critical review and a patient-specific case. Journal of Clinical Medicine, 10(10). https://doi.org/10.3390/jcm10102169

35. Filteau, M., Diss, G., Torres-Quiroz, F., Dubé, A. K., Schraffl, A., Bachmann, V. A., Gagnon-Arsenault, I., Chrétien, A.-È., Steunou, A.-L., Dionne, U., Côté, J., Bisson, N., Stefan, E., & Landry, C. R. (2015). Systematic identification of signal integration by protein kinase A. Proceedings of the National Academy of Sciences, 112(14), 4501–4506. https://doi.org/10.1073/pnas.1409938112

36. Franjić, S. (2023). Ovarian Cancer is the Deadliest of all Gynecological Tumors. Mathews Journal of Gynecology & Obstetrics, 7(1). https://doi.org/10.30654/MJGO.10022

37. Fultang, N., Chakraborty, M., & Peethambaran, B. (2021). Regulation of cancer stem cells in triple negative breast cancer. Cancer Drug Resistance. https://doi.org/10.20517/cdr.2020.106

38. Gan, D.-M., Zhang, P.-P., Zhang, J.-P., Ding, S.-X., Fang, J., & Liu, Y. (2021). KISS1/KISS1R mediates Sertoli cell apoptosis via the PI3K/AKT signalling pathway in a high glucose environment. Molecular Medicine Reports, 23(6), 477. https://doi.org/10.3892/mmr.2021.12116

39. Golzar, F., & Javanmard, S. (2015). The Effects of kisspeptin-10 on Migration and Proliferation of Endothelial Cell. Advanced Biomedical Research, 4(1), 41. https://doi.org/10.4103/2277-9175.151250

40. Gottsch, M. L., Clifton, D. K., & Steiner, R. A. (2009). From KISS1 to kisspeptins: An historical perspective and suggested nomenclature. Peptides, 30(1), 4–9. https://doi.org/10.1016/j.peptides.2008.06.016

41. Grech, N., Dalli, T., Mizzi, S., Meilak, L., Calleja, N., & Zrinzo, A. (2020). Rising Incidence of Glioblastoma Multiforme in a Well-Defined Population. Cureus. https://doi.org/10.7759/cureus.8195

42. Guan, X. (2015). Cancer metastases: challenges and opportunities. Acta Pharmaceutica Sinica B, 5(5), 402–418. https://doi.org/10.1016/j.apsb.2015.07.005

43. Guertin, D. A., & Wellen, K. E. (2023). Acetyl-CoA metabolism in cancer. Nature Reviews Cancer. https://doi.org/10.1038/s41568-022-00543-5

44. Guo, C., Wu, G., & Liu, T. (2025). Kisspeptin 10 Inhibited the Proliferation, Migration, and Stemness of Esophageal Cancer Cells via Regulating the SIX1/Wnt/β-Catetin Signaling. Journal of Biochemical and Molecular Toxicology, 39(4). https://doi.org/10.1002/jbt.70244

45. Guo, X., Liu, Z., Li, X., Zhou, B., & Chen, J. (2026). Metabolic vulnerabilities in ovarian cancer decoding the nexus between nutrient adaptation and therapy resistance. Journal of Advanced Research. https://doi.org/10.1016/j.jare.2026.01.047

46. Guo, Z., Zhu, Z., Lin, X., Wang, S., Wen, Y., Wang, L., Zhi, L., & Zhou, J. (2024). Tumor microenvironment and immunotherapy for triple-negative breast cancer. Biomarker Research, 12(1), 166. https://doi.org/10.1186/s40364-024-00714-6

47. Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of Cancer: The Next Generation. Cell, 144(5), 646–674. https://doi.org/10.1016/j.cell.2011.02.013

48. Harihar, S., & Welch, D. R. (2023). KISS1 metastasis suppressor in tumor dormancy: a potential therapeutic target for metastatic cancers? Cancer and Metastasis Reviews, 42(1), 183–196. https://doi.org/10.1007/s10555-023-10090-6

49. Hassn Mesrati, M., Syafruddin, S. E., Mohtar, M. A., & Syahir, A. (2021). CD44: A Multifunctional Mediator of Cancer Progression. Biomolecules, 11(12), 1850. https://doi.org/10.3390/biom11121850

50. He, Y., Zhu, Q., Chen, M., Huang, Q., Wang, W., Li, Q., Huang, Y., & Di, W. (2016). The changing 50% inhibitory concentration (IC50) of cisplatin: a pilot study on the artifacts of the MTT assay and the precise measurement of density-dependent chemoresistance in ovarian cancer. Oncotarget, 7(43), 70803–70821. https://doi.org/10.18632/oncotarget.12223

51. Hsu, P.-C., Tsai, C.-C., Lin, Y.-H., & Kuo, C.-Y. (2025). Therapeutic Targeting of Apoptosis, Autophagic Cell Death, Necroptosis, Pyroptosis, and Ferroptosis Pathways in Oral Squamous Cell Carcinoma: Molecular Mechanisms and Potential Strategies. Biomedicines, 13(7), 1745. https://doi.org/10.3390/biomedicines13071745

52. Hu, K.-L., Chang, H.-M., Zhao, H.-C., Yu, Y., Li, R., & Qiao, J. (2019). Potential roles for the kisspeptin/kisspeptin receptor system in implantation and placentation. Human Reproduction Update, 25(3), 326–343. https://doi.org/10.1093/humupd/dmy046

53. Huang, Y., Hong, W., & Wei, X. (2022). The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis. Journal of Hematology & Oncology, 15(1), 129. https://doi.org/10.1186/s13045-022-01347-8

54. Hussen, B. M., Hidayat, H. J., Salihi, A., Sabir, D. K., Taheri, M., & Ghafouri-Fard, S. (2021). MicroRNA: A signature for cancer progression. Biomedicine & Pharmacotherapy, 138, 111528. https://doi.org/10.1016/j.biopha.2021.111528

55. Ibáñez de Opakua, A., Merino, N., Villate, M., Cordeiro, T. N., Ormaza, G., Sánchez-Carbayo, M., Diercks, T., Bernadó, P., & Blanco, F. J. (2017). The metastasis suppressor KISS1 is an intrinsically disordered protein slightly more extended than a random coil. PLOS ONE, 12(2), e0172507. https://doi.org/10.1371/journal.pone.0172507

56. Imran, S. A. M., Yazid, M. D., Idrus, R. B. H., Maarof, M., Nordin, A., Razali, R. A., & Lokanathan, Y. (2021). Is There an Interconnection between Epithelial–Mesenchymal Transition (EMT) and Telomere Shortening in Aging? International Journal of Molecular Sciences, 22(8), 3888. https://doi.org/10.3390/ijms22083888

57. Inda, M. del M., Bonavia, R., & Seoane, J. (2014). Glioblastoma multiforme:A look inside its heterogeneous nature. In Cancers (Vol. 6, Number 1, pp. 226–239). https://doi.org/10.3390/cancers6010226

58. Iseki, Y., Shibutani, M., Maeda, K., Nagahara, H., Ikeya, T., & Hirakawa, K. (2017). Significance of E-cadherin and CD44 expression in patients with unresectable metastatic colorectal cancer. Oncology Letters, 14(1), 1025–1034. https://doi.org/10.3892/ol.2017.6269

59. Iseki, Y., Shibutani, M., Maeda, K., Nagahara, H., Ikeya, T., & Hirakawa, K. (2017). Significance of E-cadherin and CD44 expression in patients with unresectable metastatic colorectal cancer. Oncology Letters, 14(1), 1025–1034. https://doi.org/10.3892/ol.2017.6269

60. IWADATE, Y. (2016). Epithelial-mesenchymal transition in glioblastoma progression. Oncology Letters, 11(3), 1615–1620. https://doi.org/10.3892/ol.2016.4113

61. Jabeen, S., Zahid Qureshi, M., Javed, Z., Javed Iqbal, M., Ismail, M., & Ahmad Farooqi, A. (2016). Kisspeptin Mediated Signaling in Cancer. Current Topics in Medicinal Chemistry, 16(22), 2471–2476. https://doi.org/10.2174/1568026616666160212123309

62. JI, K., YE, L., MASON, M. D., & JIANG, W. G. (2013). The Kiss-1/Kiss-1R complex as a negative regulator of cell motility and cancer metastasis (Review). International Journal of Molecular Medicine, 32(4), 747–754. https://doi.org/10.3892/ijmm.2013.1472

63. Jiang, Y., Berk, M., Singh, L. S., Tan, H., Yin, L., Powell, C. T., & Xu, Y. (2005). KiSS1 suppresses metastasis in human ovarian cancer via inhibition of protein kinase C alpha. Clinical and Experimental Metastasis, 22(5), 369–376. https://doi.org/10.1007/s10585-005-8186-4

64. Jones, P. L., Jan Veenstra, G. C., Wade, P. A., Vermaak, D., Kass, S. U., Landsberger, N., Strouboulis, J., & Wolffe, A. P. (1998). Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. http://genetics.nature.com

65. Jørgensen, C. L. T., Forsare, C., Bendahl, P.-O., Falck, A.-K., Fernö, M., Lövgren, K., Aaltonen, K., & Rydén, L. (2020). Expression of epithelial-mesenchymal transition-related markers and phenotypes during breast cancer progression. Breast Cancer Research and Treatment, 181(2), 369–381. https://doi.org/10.1007/s10549-020-05627-0

66. Kallergi, G., Papadaki, M. A., Politaki, E., Mavroudis, D., Georgoulias, V., & Agelaki, S. (2011). Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. Breast Cancer Research, 13(3), R59. https://doi.org/10.1186/bcr2896

67. Kciuk, M., Gielecińska, A., Mujwar, S., Kołat, D., Kałuzińska-Kołat, Ż., Celik, I., & Kontek, R. (2023). Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity. Cells, 12(4), 659. https://doi.org/10.3390/cells12040659

68. Kepuladze, S., Burkadze, G., & Kokhreidze, I. (2024). Epithelial-Mesenchymal Transition Indexes in Triple-Negative Breast Cancer Progression and Metastases. Cureus. https://doi.org/10.7759/cureus.68761

69. Kokura, K., Kaul, S. C., Wadhwa, R., Nomura, T., Khan, M. M., Shinagawa, T., Yasukawa, T., Colmenares, C., & Ishii, S. (2001). The Ski Protein Family Is Required for MeCP2-mediated Transcriptional Repression. Journal of Biological Chemistry, 276(36), 34115–34121. https://doi.org/10.1074/jbc.M105747200

70. Le Bras, G. F., Taubenslag, K. J., & Andl, C. D. (2012). The regulation of cell-cell adhesion during epithelial-mesenchymal transition, motility and tumor progression. Cell Adhesion & Migration, 6(4), 365–373. https://doi.org/10.4161/cam.21326

71. Lee, Y.-L., Lin, K.-L., Wu, B.-N., Chuang, S.-M., Wu, W.-J., Lee, Y.-C., Ho, W.-T., & Juan, Y.-S. (2018). Epigallocatechin-3-gallate alleviates bladder overactivity in a rat model with metabolic syndrome and ovarian hormone deficiency through mitochondria apoptosis pathways. Scientific Reports, 8(1), 5358. https://doi.org/10.1038/s41598-018-23800-w

72. Li, F., Tian, J., Zhang, L., He, H., & Song, D. (2024). A multi-omics approach to reveal critical mechanisms of activator protein 1 (AP-1). Biomedicine & Pharmacotherapy, 178, 117225. https://doi.org/10.1016/j.biopha.2024.117225

73. Li, S., Zhang, J., Wang, Y., & Wan, X. (2010). The role of microRNAs in ovarian cancer initiation and progression. Journal of Cellular and Molecular Medicine, 14(9), 2240–2249. https://doi.org/10.1111/j.1582-4934.2010.01058.x

74. Li, X., Sun, X., & Carmeliet, P. (2019). Hallmarks of Endothelial Cell Metabolism in Health and Disease. Cell Metabolism, 30(3), 414–433. https://doi.org/10.1016/j.cmet.2019.08.011

75. Liska, O., Bohár, B., Hidas, A., Korcsmáros, T., Papp, B., Fazekas, D., & Ari, E. (2022). TFLink: an integrated gateway to access transcription factor–target gene interactions for multiple species. Database, 2022. https://doi.org/10.1093/database/baac083

76. Liu, H., Xia, J., Wang, T., Li, W., Song, Y., & Tan, G. (2019). Differentiation of human glioblastoma U87 cells into cholinergic neuron. Neuroscience Letters, 704, 1–7. https://doi.org/10.1016/j.neulet.2019.03.049

77. Liu, R., Shi, P., Wang, Z., Yuan, C., & Cui, H. (2021). Molecular Mechanisms of MYCN Dysregulation in Cancers. Frontiers in Oncology, 10. https://doi.org/10.3389/fonc.2020.625332

78. Liu, Y., He, J., Chen, J., Chen, T., Li, W., Yang, Z., & Zeng, F. (2025). Programmed cell death in triple-negative breast cancer. Cellular & Molecular Biology Letters, 30(1), 111. https://doi.org/10.1186/s11658-025-00789-5

79. Lodrini, M., Oehme, I., Schroeder, C., Milde, T., Schier, M. C., Kopp-Schneider, A., Schulte, J. H., Fischer, M., De Preter, K., Pattyn, F., Castoldi, M., Muckenthaler, M. U., Kulozik, A. E., Westermann, F., Witt, O., & Deubzer, H. E. (2013). MYCN and HDAC2 cooperate to repress miR-183 signaling in neuroblastoma. Nucleic Acids Research, 41(12), 6018–6033. https://doi.org/10.1093/nar/gkt346

80. Loh, C.-Y., Chai, J., Tang, T., Wong, W., Sethi, G., Shanmugam, M., Chong, P., & Looi, C. (2019). The E-Cadherin and N-Cadherin Switch in Epithelial-to-Mesenchymal Transition: Signaling, Therapeutic Implications, and Challenges. Cells, 8(10), 1118. https://doi.org/10.3390/cells8101118

81. López-Reig, R., & López-Guerrero, J. A. (2020). The hallmarks of ovarian cancer: proliferation and cell growth. European Journal of Cancer Supplements, 15, 27–37. https://doi.org/10.1016/j.ejcsup.2019.12.001

82. Loret, N., Denys, H., Tummers, P., & Berx, G. (2019). The Role of Epithelial-to-Mesenchymal Plasticity in Ovarian Cancer Progression and Therapy Resistance. Cancers, 11(6), 838. https://doi.org/10.3390/cancers11060838

83. Łukasiewicz, S., Czeczelewski, M., Forma, A., Baj, J., Sitarz, R., & Stanisławek, A. (2021). Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review. Cancers, 13(17), 4287. https://doi.org/10.3390/cancers13174287

84. Luo, D., & Ge, W. (2020). MeCP2 promotes colorectal cancer metastasis by modulating zeb1 transcription. Cancers, 12(3). https://doi.org/10.3390/cancers12030758

85. Ly, T., Harihar, S., & Welch, D. R. (2020). KISS1 in metastatic cancer research and treatment: potential and paradoxes. Cancer and Metastasis Reviews, 39(3), 739–754. https://doi.org/10.1007/s10555-020-09868-9

86. Maqsood, Q., Khan, M. U., Fatima, T., Khalid, S., & Malik, Z. I. (2025). Recent Insights Into Breast Cancer: Molecular Pathways, Epigenetic Regulation, and Emerging Targeted Therapies. Breast Cancer: Basic and Clinical Research, 19. https://doi.org/10.1177/11782234251355663

87. Mead, E. J., Maguire, J. J., Kuc, R. E., & Davenport, A. P. (2007a). Kisspeptins: a multifunctional peptide system with a role in reproduction, cancer and the cardiovascular system. British Journal of Pharmacology, 151(8), 1143–1153. https://doi.org/10.1038/sj.bjp.0707295

88. Mead, E. J., Maguire, J. J., Kuc, R. E., & Davenport, A. P. (2007b). Kisspeptins: a multifunctional peptide system with a role in reproduction, cancer and the cardiovascular system. British Journal of Pharmacology, 151(8), 1143–1153. https://doi.org/10.1038/sj.bjp.0707295

89. Mitra, A. K. (2016). Ovarian Cancer Metastasis: A Unique Mechanism of Dissemination. In Tumor Metastasis. InTech. https://doi.org/10.5772/64700

90. Motti, M. L., & Meccariello, R. (2019). Minireview: The Epigenetic Modulation of KISS1 in Reproduction and Cancer. International Journal of Environmental Research and Public Health, 16(14), 2607. https://doi.org/10.3390/ijerph16142607

91. Moufarrij, S., & O'Cearbhaill, R. E. (2023). Novel Therapeutics in Ovarian Cancer: Expanding the Toolbox. Current Oncology, 31(1), 97–114. https://doi.org/10.3390/curroncol31010007

92. Mustafa, M., Ahmad, R., Tantry, I. Q., Ahmad, W., Siddiqui, S., Alam, M., Abbas, K., Moinuddin, Hassan, Md. I., Habib, S., & Islam, S. (2024). Apoptosis: A Comprehensive Overview of Signaling Pathways, Morphological Changes, and Physiological Significance and Therapeutic Implications. Cells, 13(22), 1838. https://doi.org/10.3390/cells13221838

93. Nameki, R., Chang, H., Reddy, J., Corona, R. I., & Lawrenson, K. (2021). Transcription factors in epithelial ovarian cancer: histotype-specific drivers and novel therapeutic targets. Pharmacology & Therapeutics, 220, 107722. https://doi.org/10.1016/j.pharmthera.2020.107722

94. Pan, G., Liu, Y., Shang, L., Zhou, F., & Yang, S. (2021). EMT-associated microRNAs and their roles in cancer stemness and drug resistance. Cancer Communications, 41(3), 199–217. https://doi.org/10.1002/cac2.12138

95. Pandey, S., & Pruitt, K. (n.d.). Functional assessment of MeCP2 in Rett syndrome and cancers of breast, colon 1 and prostate. In Biochem. Cell Biol. Downloaded from www.nrcresearchpress.com by. Retrieved www.nrcresearchpress.com

96. Patel, P. S., Matson, J. P., Ran, X., Stanzione, M., Kawale, A. S., Wang, M., Saxena, S., Sander, C., Curtis, J., Hopkins, J. L., Wong, E., Corcoran, R. B., Haber, D. A., Dyson, N. J., Maheswaran, S., & Zou, L. (2026). ATR Safeguards Epithelial-to-Mesenchymal Transition by Countering R-loops and Enabling Transcription Reprogramming. Journal of Clinical Investigation. https://doi.org/10.1172/JCI192225

97. Pearson, J. R. D., & Regad, T. (2017). Targeting cellular pathways in glioblastoma multiforme. In Signal Transduction and Targeted Therapy (Vol. 2). Springer Nature. https://doi.org/10.1038/sigtrans.2017.40

98. Phi, L. T. H., Sari, I. N., Yang, Y.-G., Lee, S.-H., Jun, N., Kim, K. S., Lee, Y. K., & Kwon, H. Y. (2018). Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment. Stem Cells International, 2018, 1–16. https://doi.org/10.1155/2018/5416923

99. Pistritto, G., Trisciuoglio, D., Ceci, C., Garufi, A., & D'Orazi, G. (2016). Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies. Aging, 8(4), 603–619. https://doi.org/10.18632/aging.100934

100. Ponta, H., Sherman, L., & Herrlich, P. A. (2003). CD44: From adhesion molecules to signalling regulators. Nature Reviews Molecular Cell Biology, 4(1), 33–45. https://doi.org/10.1038/nrm1004

101. Pouyan, A., Ghorbanlo, M., Eslami, M., Jahanshahi, M., Ziaei, E., Salami, A., Mokhtari, K., Shahpasand, K., Farahani, N., Meybodi, T. E., Entezari, M., Taheriazam, A., Hushmandi, K., & Hashemi, M. (2025). Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies. Molecular Cancer, 24(1), 58. https://doi.org/10.1186/s12943-025-02267-0

102. Prabhu, V. V., Sakthive, K. M., & Guruvayoorappan, C. (2013). Kisspeptins (KiSS-1): Essential players in suppressing tumor metastasis. In Asian Pacific Journal of Cancer Prevention (Vol. 14, Issue 11, pp. 6215–6220). Asian Pacific Organization for Cancer Prevention. https://doi.org/10.7314/APJCP.2013.14.11.6215

103. Primeaux, M., Gowrikumar, S., & Dhawan, P. (2022). Role of CD44 isoforms in epithelial-mesenchymal plasticity and metastasis. Clinical & Experimental Metastasis, 39(3), 391–406. https://doi.org/10.1007/s10585-022-10146-x

104. Pu, M., Chen, J., Tao, Z., Miao, L., Qi, X., Wang, Y., & Ren, J. (2019). Regulatory network of miRNA on its target: coordination between transcriptional and post-transcriptional regulation of gene expression. Cellular and Molecular Life Sciences, 76(3), 441–451. https://doi.org/10.1007/s00018-018-2940-7

105. Ramaesh, T., Logie, J. J., Roseweir, A. K., Millar, R. P., Walker, B. R., Hadoke, P. W. F., & Reynolds, R. M. (2010). Kisspeptin-10 Inhibits Angiogenesis in Human Placental Vessels ex Vivo and Endothelial Cells in Vitro. Endocrinology, 151(12), 5927–5934. https://doi.org/10.1210/en.2010-0565

106. Ramirez Moreno, M., Stempor, P. A., & Bulgakova, N. A. (2021). Interactions and Feedbacks in E-Cadherin Transcriptional Regulation. Frontiers in Cell and Developmental Biology, 9. https://doi.org/10.3389/fcell.2021.701175

107. Rather, M. A., Basha, S. H., Bhat, I. A., Sharma, N., Nandanpawar, P., Badhe, M., P, G. B., Chaudhari, A., Sundaray, J. K., & Sharma, R. (2017a). Characterization, molecular docking, dynamics simulation and metadynamics of kisspeptin receptor with kisspeptin.

International Journal of Biological Macromolecules, 101, 241–253. https://doi.org/10.1016/j.ijbiomac.2017.03.102

108. Rather, M. A., Basha, S. H., Bhat, I. A., Sharma, N., Nandanpawar, P., Badhe, M., P, G.-B., Chaudhari, A., Sundaray, J. K., & Sharma, R. (2017b). Characterization, molecular docking, dynamics simulation and metadynamics of kisspeptin receptor with kisspeptin. International Journal of Biological Macromolecules, 101, 241–253. https://doi.org/10.1016/j.ijbiomac.2017.03.102

109. Raza, S. M., Lang, F. F., Aggarwal, B. B., Fuller, G. N., Wildrick, D. M., & Sawaya, R. (n.d.). LITERATURE REVIEW NECROSIS AND GLIOBLASTOMA: A FRIEND OR A FOE? A REVIEW AND A HYPOTHESIS. https://doi.org/10.1227/01.NEU.0000017462.65730.06

110. Rios Garcia, M., Steinbauer, B., Srivastava, K., Singhal, M., Mattijssen, F., Maida, A., Christian, S., Hess-Stumpp, H., Augustin, H. G., Müller-Decker, K., Nawroth, P. P., Herzig, S., & Berriel Diaz, M. (2017). Acetyl-CoA Carboxylase 1-Dependent Protein Acetylation Controls Breast Cancer Metastasis and Recurrence. Cell Metabolism, 26(6), 842-855.e5. https://doi.org/10.1016/j.cmet.2017.09.018

111. Rubtsova, S. N., Zhitnyak, I. Y., & Gloushankova, N. A. (2022). Dual role of E-cadherin in cancer cells. Tissue Barriers, 10(4). https://doi.org/10.1080/21688370.2021.2005420

112. Scheiber, M. N., Watson, P. M., Rumboldt, T., Stanley, C., Wilson, R. C., Findlay, V. J., Anderson, P. E., & Watson, D. K. (2014). FLI1 Expression is Correlated with Breast Cancer Cellular Growth, Migration, and Invasion and Altered Gene Expression. Neoplasia, 16(10), 801–813. https://doi.org/10.1016/j.neo.2014.08.007

113. Scheiber, M. N., Watson, P. M., Rumboldt, T., Stanley, C., Wilson, R. C., Findlay, V. J., Anderson, P. E., & Watson, D. K. (2014). FLI1 Expression is Correlated with Breast Cancer Cellular Growth, Migration, and Invasion and Altered Gene Expression. Neoplasia, 16(10), 801–813. https://doi.org/10.1016/j.neo.2014.08.007

114. Schweiger, M. W., & Tannous, B. A. (2020). Small but Fierce: Tracking the Role of Extracellular Vesicles in Glioblastoma Progression and Therapeutic Resistance. In Advanced Biosystems (Vol. 4, Number 12). Wiley-VCH Verlag. https://doi.org/10.1002/adbi.202000035

115. Sedeta, E. T., Jobre, B., & Avezbakiyev, B. (2023). Breast cancer: Global patterns of incidence, mortality, and trends. Journal of Clinical Oncology, 41(16_suppl), 10528–10528. https://doi.org/10.1200/JCO.2023.41.16_suppl.10528

116. Seker-Polat, F., Pinarbasi Degirmenci, N., Solaroglu, I., & Bagci-Onder, T. (2022). Tumor Cell Infiltration into the Brain in Glioblastoma: From Mechanisms to Clinical Perspectives. Cancers, 14(2), 443. https://doi.org/10.3390/cancers14020443

117. Shah, H., Mohan, A. M., Buch, L., Ramachandran, A. V., & Pandya, P. (2025). Exogenous kisspeptin-10 treatment shows pleiotropy via induction of KISS1 expression, metastasis suppression, and promotes apoptosis in triple-negative breast cancer. Scientific Reports, 15(1), 35182. https://doi.org/10.1038/s41598-025-19140-1

118. Shah, H., Mohan, A. M., Shah, R., Mehta, D., Ramachandran, A. V., & Pandya, P. (2026). Integrated transcriptomics and miRNA-mRNA network analysis reveals Kisspeptin-10 mediated regulation of EMT and apoptosis in glioblastoma. Computational Biology and Chemistry, 121, 108826. https://doi.org/10.1016/j.compbiolchem.2025.108826

119. Shah, H., Mohan, A. M., Shah, R., Mehta, D., Ramachandran, A. V., & Pandya, P. (2026). Integrated transcriptomics and miRNA-mRNA network analysis reveals Kisspeptin-10 mediated regulation of EMT and apoptosis in glioblastoma. Computational Biology and Chemistry, 121, 108826. https://doi.org/10.1016/j.compbiolchem.2025.108826

120. Shah, H., Pillai, P., Buch, L., Ramachandran, A. V., & Pandya, P. (2025). Deciphering protein–DNA interactions of KISS1 with transcription factors through molecular docking, molecular dynamics simulations, and gene expression analysis. Journal of Biomolecular Structure and Dynamics, 1–17. https://doi.org/10.1080/07391102.2025.2553344

121. Shan, W., Jiang, Y., Yu, H., Huang, Q., Liu, L., Guo, X., Li, L., Mi, Q., Zhang, K., & Yang, Z. (2017). Original Article HDAC2 overexpression correlates with aggressive clinicopathological features and DNA-damage response pathway of breast cancer. In Am J Cancer Res (Vol. 7, Issue 5). www.ajcr.us/

122. Silverman, D. A., Martinez, V. K., Dougherty, P. M., Myers, J. N., Calin, G. A., & Amit, M. (2021). Cancer-Associated Neurogenesis and Nerve-Cancer Cross-talk. Cancer Research, 81(6), 1431–1440. https://doi.org/10.1158/0008-5472.CAN-20-2793

123. Singh, R., Letai, A., & Sarosiek, K. (2019). Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nature Reviews Molecular Cell Biology, 20(3), 175–193. https://doi.org/10.1038/s41580-018-0089-8

124. Sipos, D., Raposa, B. L., Freihat, O., Simon, M., Mekis, N., Cornacchione, P., & Kovács, Á. (2025). Glioblastoma: Clinical Presentation, Multidisciplinary Management, and Long-Term Outcomes. Cancers, 17(1), 146. https://doi.org/10.3390/cancers17010146

125. SONG, G.-Q., & ZHAO, Y. (2015). Kisspeptin-10 inhibits the migration of breast cancer cells by regulating epithelial-mesenchymal transition. Oncology Reports, 33(2), 669–674. https://doi.org/10.3892/or.2014.3619

126. Song, G.-Q., & Zhao, Y. (2016). Kisspeptin 10 inhibits the Warburg effect in breast cancer through the Smad signaling pathway: both in vitro and in vivo. American Journal of Translational Research, 8(1), 188–195.

127. Stathaki, M., Stamatiou, M. E., Magioris, G., Simantiris, S., Syrigos, N., Dourakis, S., Koutsilieris, M., & Armakolas, A. (2019). The role of kisspeptin system in cancer biology. Critical Reviews in Oncology/Hematology, 142, 130–140. https://doi.org/10.1016/j.critrevonc.2019.07.015

128. Steeg, P. S., Ouatas, T., Halverson, D., Palmieri, D., & Salerno, M. (2003). Metastasis Suppressor Genes: Basic Biology and Potential Clinical Use. Clinical Breast Cancer, 4(1), 51–62. https://doi.org/10.3816/CBC.2003.n.012

129. Stern, J. L., Theodorescu, D., Vogelstein, B., Papadopoulos, N., & Cech, T. R. (2015). Mutation of the TERT promoter, switch to active chromatin, and monoallelic TERT expression in multiple cancers. Genes & Development, 29(21), 2219–2224. https://doi.org/10.1101/gad.269498.115

130. Sun, J., Ding, J., Shen, Q., Wang, X., Wang, M., Huang, Y., Zhang, X., Zhu, H., Zhang, F., Wu, D., Peng, M., Zhang, Z., Yuan, Y., Li, W., She, Z.-G., Zhang, X.-J., Li, H., Zhang, P., & Huang, Z. (2023). Decreased propionyl-CoA metabolism facilitates metabolic reprogramming and promotes hepatocellular carcinoma. Journal of Hepatology, 78(3), 627–642. https://doi.org/10.1016/j.jhep.2022.11.017

131. Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249. https://doi.org/10.3322/caac.21660

132. Tan, D. S., Agarwal, R., & Kaye, S. B. (2006). Mechanisms of transcoelomic metastasis in ovarian cancer. The Lancet Oncology, 7(11), 925–934. https://doi.org/10.1016/S1470-2045(06)70939-1

133. Tang, Z., Li, C., Kang, B., Gao, G., Li, C., & Zhang, Z. (2017). GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Research, 45(W1), W98–W102. https://doi.org/10.1093/nar/gkx247

134. Tng, E. (2015). Kisspeptin signalling and its roles in humans. Singapore Medical Journal, 56(12), 649–656. https://doi.org/10.11622/smedj.2015183

135. Tomikawa, J., Uenoyama, Y., Ozawa, M., Fukanuma, T., Takase, K., Goto, T., Abe, H., Ieda, N., Minabe, S., Deura, C., Inoue, N., Sanbo, M., Tomita, K., Hirabayashi, M., Tanaka, S., Imamura, T., Okamura, H., Maeda, K. I., & Tsukamura, H. (2012). Epigenetic regulation of Kiss1 gene expression mediating estrogen-positive feedback action in the mouse brain. Proceedings of the National Academy of Sciences of the United States of America, 109(20). https://doi.org/10.1073/pnas.1114245109

136. Tornesello, M. L., Cerasuolo, A., Starita, N., Amiranda, S., Bonelli, P., Tuccillo, F. M., Buonaguro, F. M., Buonaguro, L., & Tornesello, A. L. (2023). Reactivation of telomerase reverse transcriptase expression in cancer: the role of TERT promoter mutations. Frontiers in Cell and Developmental Biology, 11. https://doi.org/10.3389/fcell.2023.1286683

137. Ulm, M., Ramesh, A. V, McNamara, K. M., Ponnusamy, S., Sasano, H., & Narayanan, R. (2019). Therapeutic advances in hormone-dependent cancers: focus on prostate, breast and ovarian cancers. Endocrine Connections, 8(2), R10–R26. https://doi.org/10.1530/EC-18-0425

138. Usman, S., Waseem, N. H., Nguyen, T. K. N., Mohsin, S., Jamal, A., Teh, M.-T., & Waseem, A. (2021). Vimentin Is at the Heart of Epithelial Mesenchymal Transition (EMT) Mediated Metastasis. Cancers, 13(19), 4985. https://doi.org/10.3390/cancers13194985

139. Vaidya, K. S., & Welch, D. R. (2007). Metastasis Suppressors and Their Roles in Breast Carcinoma. Journal of Mammary Gland Biology and Neoplasia, 12(2–3), 175–190. https://doi.org/10.1007/s10911-007-9049-1

140. van Zijl, F., Krupitza, G., & Mikulits, W. (2011). Initial steps of metastasis: Cell invasion and endothelial transmigration. Mutation Research/Reviews in Mutation Research, 728(1–2), 23–34. https://doi.org/10.1016/j.mrrev.2011.05.002

141. Vishnoi, K., Viswakarma, N., Rana, A., & Rana, B. (2020). Transcription Factors in Cancer Development and Therapy. Cancers, 12(8), 2296. https://doi.org/10.3390/cancers12082296

142. Wang, Y., Jiang, R., Wang, Q., Li, Y., Sun, Z., & Zhao, H. (2021a). Silencing LINC01021 inhibits gastric cancer through upregulation of KISS1 expression by blocking CDK2-dependent phosphorylation of CDX2. Molecular Therapy Nucleic Acids, 24, 832–844. https://doi.org/10.1016/j.omtn.2021.01.025

143. Wang, Y., Jiang, R., Wang, Q., Li, Y., Sun, Z., & Zhao, H. (2021b). Silencing LINC01021 inhibits gastric cancer through upregulation of KISS1 expression by blocking CDK2-dependent phosphorylation of CDX2. Molecular Therapy - Nucleic Acids, 24, 832–844. https://doi.org/10.1016/j.omtn.2021.01.025

144. Wierstra, I. (2008). Sp1: Emerging roles—Beyond constitutive activation of TATA-less housekeeping genes. Biochemical and Biophysical Research Communications, 372(1), 1–13. https://doi.org/10.1016/j.bbrc.2008.03.074

145. WU, D., LIU, L., REN, C., KONG, D., ZHANG, P., JIN, X., WANG, T., & ZHANG, G. (2016). Epithelial-mesenchymal interconversions and the regulatory function of the ZEB family during the development and progression of ovarian cancer. Oncology Letters, 11(2), 1463–1468. https://doi.org/10.3892/ol.2016.4092

146. Xia, Y., Wang, J., Liu, T.-J., Yung, W. K. A., Hunter, T., & Lu, Z. (2007). c-Jun Downregulation by HDAC3-Dependent Transcriptional Repression Promotes Osmotic Stress-Induced Cell Apoptosis. Molecular Cell, 25(2), 219–232. https://doi.org/10.1016/j.molcel.2007.01.005

147. Xu, Y., Nijhuis, A., & Keun, H. C. (2022). RNA-binding motif protein 39 (RBM39): An emerging cancer target. British Journal of Pharmacology, 179(12), 2795–2812. https://doi.org/10.1111/bph.15331

148. Xue, C., Chu, Q., Shi, Q., Zeng, Y., Lu, J., & Li, L. (2025). Wnt signaling pathways in biology and disease: mechanisms and therapeutic advances. Signal Transduction and Targeted Therapy, 10(1), 106. https://doi.org/10.1038/s41392-025-02142-w

149. Yang, Y., Li, S., Wang, Y., Zhao, Y., & Li, Q. (2022). Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective. In Signal Transduction and Targeted Therapy (Vol. 7, Issue 1). Springer Nature. https://doi.org/10.1038/s41392-022-01168-8

150. Yeung, K. T., & Yang, J. (2017). Epithelial–mesenchymal transition in tumor metastasis. Molecular Oncology, 11(1), 28–39. https://doi.org/10.1002/1878-0261.12017

151. Yoon, H. G., Cheong, J. H., Ryu, J. Il, Won, Y. D., Min, K.-W., & Han, M.-H. (2023). The genes significantly associated with an improved prognosis and long-term survival of glioblastoma. PLOS ONE, 18(11), e0295061. https://doi.org/10.1371/journal.pone.0295061

152. Yu, H., Xie, M., Liufu, X., Xu, Y., & Chen, L. (2025). Kisspeptin-10 Prevents the Development of Cerebral Aneurysms by Reducing the Expression of Egr-1. CNS Neuroscience & Therapeutics, 31(5). https://doi.org/10.1111/cns.70413

153. Yu, J., Li, S., Xu, Z., Guo, J., Li, X., Wu, Y., Zheng, J., & Sun, X. (2021). CDX2 inhibits epithelial–mesenchymal transition in colorectal cancer by modulation of Snail expression and β-catenin stabilisation via transactivation of PTEN expression. British Journal of Cancer, 124(1), 270–280. https://doi.org/10.1038/s41416-020-01148-1

154. Zhang, J., Tian, X.-J., & Xing, J. (2016). Signal Transduction Pathways of EMT Induced by TGF-β, SHH, and WNT and Their Crosstalks. Journal of Clinical Medicine, 5(4), 41. https://doi.org/10.3390/jcm5040041

155. Zhang, Y., Xu, L., Li, A., & Han, X. (2019). The roles of ZEB1 in tumorigenic progression and epigenetic modifications. In Biomedicine and Pharmacotherapy (Vol. 110, pp. 400–408). Elsevier Masson SAS. https://doi.org/10.1016/j.biopha.2018.11.112

156. Zhao, H. fu, Wang, J., Shao, W., Wu, C. peng, Chen, Z. ping, To, S. shun T., & Li, W. ping. (2017). Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: Current preclinical and clinical development. In Molecular Cancer (Vol. 16, Number 1). BioMed Central Ltd. https://doi.org/10.1186/s12943-017-0670-3.